Arrowhead's two Phase 3 plozasiran SHTG trials both show completed status this week

Arrowhead Pharmaceuticals had two Phase 3 trials reach completed status this week, plus a newly posted Phase 2 study and a continuing recruitment update.

• Arrowhead's Phase 3 "SHASTA-3" trial (NCT06347003) of plozasiran injection in adults with severe hypertriglyceridemia is now listed as completed, with actual primary completion on 2026-06-12. The trial enrolled 446 participants.¹ Its primary outcome was percent change in fasting serum triglyceride levels from baseline to Month 12 compared to placebo.¹
• Arrowhead's Phase 3 "SHASTA-4" trial (NCT06347016) of plozasiran injection in the same condition is also now listed as completed, with actual primary completion on 2026-06-17. The trial enrolled 311 participants.²
• Arrowhead's Phase 3 "SPRUCE" study (NCT07473843) is recruiting adolescents aged 12 to under 18 with homozygous familial hypercholesterolemia. The study will evaluate zodasiran subcutaneous injection in participants with genetically or clinically diagnosed homozygous familial hypercholesterolemia and LDL-C at or above 116 milligrams per deciliter on maximally tolerated lipid-lowering therapy.³ Estimated enrollment is 10 participants.³
• Arrowhead's Phase 2 trial of ARO-INHBE (NCT07859813) is not yet recruiting. The study is titled "A Phase 2, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis With or Without Type 2 Diabetes Mellitus." Estimated enrollment is 252 participants.⁴ Its primary outcome is percent change from baseline in liver fat content by MRI-PDFF at Week 48.⁴